Shots:
- CareDx has entered into a definitive agreement to acquire Naveris, extending CareDx’s Precision Medicine Testing Services strategy into specialty oncology
- As per the deal, CareDx will acquire Naveris for $160M upfront & up to $100M in revenue milestones; closing is expected in Q3’26
- Naveris’ liquid biopsy platform uses TTMV DNA to detect viral DNA fragments from tumor tissue in blood, enabling accurate biomarker-based management of HPV-driven cancers from diagnosis through post-treatment MRD surveillance
Ref: Businesswire | Image: Naveris| Press Release
Related News: CareDx to Divest Lab Products Unit to EuroBio Scientific for $170M
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
